Drug interactions with anxiolytics and hypnotics (Table 8.14L)
| Anxiolytics include benzodiazepines and buspirone. Hypnotics include benzodiazepines, zolpidem and zopiclone. | |||
| Drug | Rating [NB1] | Interaction | Recommended action |
| 2 | Respiratory depression with benzodiazepines, especially if given parenterally. | Monitor for respiratory depression. | |
| 3 | Increase plasma concentration of alprazolam, buspirone and triazolam (CYP3A4 inhibition). | Monitor for adverse effects. Consider use of an alternative anxiolytic or hypnotic, eg lorazepam, oxazepam or temazepam. | |
| 2 | May increase plasma concentrations of alprazolam, triazolam, buspirone, zolpidem and zopiclone (CYP3A4 inhibition). | Monitor for adverse effects. Use an alternative benzodiazepine or alternative antifungal drug, eg terbinafine. | |
| Calcium channel blockers | 3 | Diltiazem and verapamil may increase plasma concentrations of buspirone and triazolam (CYP3A4 inhibition). | Monitor for adverse effects. Use an alternative calcium channel blocker or alternative anxiolytic, eg lorazepam, oxazepam or temazepam. |
| Cimetidine | 3 | Increases plasma concentrations of alprazolam, diazepam, nitrazepam and triazolam (CYP3A4 inhibition). | Monitor for adverse effects. Use an alternative H2-receptor blocker or alternative benzodiazepine, eg lorazepam, oxazepam or temazepam. |
| Clarithromycin - | |||
| Disulfiram | 3 | Decreases diazepam metabolism. | Monitor for adverse effects. Use an alternative drug, eg alprazolam, oxazepam or lorazepam. |
| ECT | 2 | Benzodiazepines raise seizure threshold, which may impair the efficacy of the ECT. | Taper and cease benzodiazepines before ECT. |
| Erythromycin - | |||
| Esomeprazole - | |||
| 2 | Increase plasma concentrations of alprazolam, triazolam, buspirone, and zopiclone (CYP3A4 inhibition). | Monitor for adverse effects. Use an alternative antibiotic, eg roxithromycin, or alternative anxiolytic, eg lorazepam, oxazepam or temazepam. | |
| MAOIs, irreversible nonselective | 3 | Hypertension reported rarely with buspirone. | Monitor for increased blood pressure or use an alternative drug. |
| Nefazodone - | |||
| Omeprazole - | |||
| 3 | Decreased clearance of diazepam reported (possibly inhibition of CYP3A, CYP2C9 or CYP2C19). | Monitor for adverse effects of diazepam or use alternative benzodiazepine or alternative proton pump inhibitor, eg rabeprazole | |
| Rifabutin, rifampicin | 3 | Increased buspirone, diazepam, nitrazepam, triazolam, zolpidem and zopiclone metabolism. Temazepam not affected. | Monitor for decreased effect of anxiolytic or hypnotic. |
| Ritonavir - | |||
| Saquinavir - | |||
| 2 | Nefazodone inhibits metabolism (CYP3A4) of alprazolam, triazolam and zopiclone. Fluoxetine and fluvoxamine increase plasma alprazolam and diazepam concentrations. Unlikely with paroxetine or sertraline. | Monitor for benzodiazepine adverse effects or use alternative anxiolytic, eg lorazepam, oxazepam or temazepam. | |
| | 3 | Several reports of adverse effects with fluoxetine and buspirone. | Monitor for increased adverse effects such as worsening of psychiatric symptoms, serotonergic effects or seizure with buspirone and fluoxetine. |
| Tramadol - | |||
| Rating 1 – Avoid combination; risk always outweighs benefit. Rating 2 – Usually avoid combination; use combination only under special circumstances. Rating 3 – Minimise risk; take action as necessary to reduce risk. | |||
Comments
Post a Comment